Clinical value of serum VILIP-1 and Hepc25 in predicting prognosis of patients with acute ischemic stroke after intravenous thrombolysis
10.3969/j.issn.1006-5725.2024.17.012
- VernacularTitle:血清视锥蛋白样蛋白1、铁调素25预测急性缺血性脑卒中患者静脉溶栓治疗预后的临床价值
- Author:
Yan LI
1
;
Xianlong XIE
;
Mengli ZHU
;
Qing SU
Author Information
1. 武汉市第一医院急诊医学科(武汉 430022)
- Keywords:
serum VILIP-1;
Hepc25;
acute ischemic stroke;
intravenous thrombolysis
- From:
The Journal of Practical Medicine
2024;40(17):2425-2429
- CountryChina
- Language:Chinese
-
Abstract:
Objective The clinical value of serum VILIP-1 and Hepc25 in predicting the prognosis of patients with Acute ischemic stroke(AIS)from intravenous thrombolysis was analyzed.Methods A total of 225 patients with acute ischemic stroke diagnosed and treated in the hospital from January 2022 to November 2023 were selected.According to Rankin Scale(mRS)grouping study,97 patients with mRS≥3 were divided into poor prognosis group and 128 patients with mRS<3 were divided into good prognosis group.The serum levels of VILIP-1 and Hepc25 were compared and their prognostic value for intravenous thrombolysis.Results After logistic regres-sion analysis,age,admission blood glucose,LYM,NIHSS score,PLT,WBC,VILIP-1,and Hepc25 were all factors affecting the prognosis of AIS patients(P<0.05);VILIP-1 and Hepc25 levels increased in patients with moderate and severe defects compared with mild defects.VILIP-1 and Hepc25 levels were higher in patients with severe defects than those with moderate defects.Compared with the poor prognosis group,the VILIP-1 and Hepc25 levels in the good prognosis group were decreased,with statistical difference(P<0.05).ROC curve analysis showed that single diagnosis of VILIP-1 and Hepc25 was lower than combined diagnosis(P<0.05).Conclusion The elevated levels of VILIP-1 and Hepc25 participate in the process of intravenous thrombolysis and affect the prognosis of patients,and can be used as clinical indicators for the prognosis of AIS patients.
